Generic Name and Formulations:
Lifitegrast 5%; oph soln.
Shire US, Inc.
Indications for XIIDRA:
Signs and symptoms of dry eye disease.
Instill 1 drop twice daily (~12hrs apart) in each eye.
<17yrs: not established.
Remove contact lens prior to use; may reinsert 15mins after administration. Pregnancy. Nursing mothers.
Lymphocyte function-associated antigen-1 (LFA-1) antagonist.
Instillation site irritation, dysgeusia, decreased visual acuity; hypersensitivity.
Single-use containers (0.2mL)—60
Clinical Pain Advisor Articles
- Opioids: Clinician Concern and Prescribing Practices
- Quantity of Opioids Prescribed Linked to Higher Patient-Reported Consumption
- Ensuring Safety During Long-Term Opioid Therapy
- Screening for Hyperglycemia Prior to Steroid Injections for Chronic Pain
- Drug Overdose Mortality Rates Rising in the United States
- Serum Vitamin D Levels and Risk for Migraine
- Rimegepant Orally Dissolving Formulation Provides Rapid Relief From Acute Migraine
- Updated Evidence-Based Recommendations for Buprenorphine Treatment
- Business Degree Increasingly Useful for Doctors
- Intervention by Pharmacists May Effectively Reduce Use of Inappropriate Medications in the Elderly
- Tips Provided for Budgeting in Medical Residency
- Give Thanks: The Role of Gratitude in Combating Burnout
- Persistent Back Pain Linked to Earlier Mortality in Older Women
- Cannabinoids May Be Effective on Experimental Pain Threshold and Tolerance, Not Intensity
- PainDETECT May Not Be Optimal to Detect Neuropathic Components of Orofacial Pain